Panitumumab - Amgen

Drug Profile

Panitumumab - Amgen

Alternative Names: ABX-EGF; Anti-EGFR monoclonal antibody - Abgenix; Clone-E7.6.3; E7.6.3; Panitumab; rHuMAb-EGFr; Vectibix

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Grupo Espanol Multidisciplinario del Cancer Digestivo; Novartis; Takeda; University of Texas M. D. Anderson Cancer Center; Wissenschaftlicher Service Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase II Anal cancer; Bladder cancer; Breast cancer; Gastric cancer; Neuroendocrine tumours; Oesophageal cancer; Rectal cancer
  • No development reported Solid tumours
  • Discontinued Head and neck cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 01 Jun 2018 Efficacy and adverse events data from the phase I/II APOLLON trial in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 01 Jun 2018 Interim efficacy and adverse events data from a phase II VITAL trial in Anal cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 31 Mar 2018 Takeda completes the phase I/II APOLLON trial in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in Japan (PO) (NCT02613221)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top